Imagene Reports FY25 Revenue of $800K, IMG-007 Leading in Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Reports FY25 revenue $800k vs $3.5M last year. "IMG-007 is now the leading receptor-targeting OX40 antagonist program in clinical development. Our approach is entirely unlike that of ADCC-enhanced anti-OX40 antibodies such as rocatinlimab: published data has shown rocatinlimab treatment causes deep depletion of T cells, while IMG-007 is a non-T cell depleting antibody. This is a fundamental, intentional, and critical difference in our molecule's design," commented Kristin Yarema, PhD, Chief Executive Officer of Imagene. "While the clinical profile of IMG-007 remains early, our safety database continues to grow and we have not seen any of the tolerability issues mechanistically linked to T cell depletion -- pyrexia, chills, ulcers -- nor have we seen any malignancies. This emerging clinical profile adds to the compelling, competitive efficacy we saw in our proof-of-concept studies in atopic dermatitis and alopecia areata. We are confident that ADAPTIVE, our Phase 2b dose-ranging study in AD, is robust and designed to well characterize IMG-007's efficacy, safety, and convenience for patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMA
Wall Street analysts forecast IMA stock price to rise
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 5.925
Low
2.00
Averages
16.00
High
30.00
Current: 5.925
Low
2.00
Averages
16.00
High
30.00
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImageneBio CEO to Present at Jefferies Global Healthcare Conference
- Conference Participation: ImageneBio CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, and engage in one-on-one meetings, aiming to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: ImageneBio is conducting a Phase 2b clinical trial of IMG-007 for patients with moderate-to-severe atopic dermatitis, which is expected to yield significant clinical data that could advance the company's product development pipeline.
- Product Characteristics: IMG-007 is a receptor-targeting monoclonal antibody with an approximately 5-week half-life and non-T cell-depleting properties, showcasing potential advantages in immunotherapy that may attract increased investor interest.
- Future Plans: The company has completed a proof-of-concept trial for IMG-007 and plans to initiate a Phase 2 study in alopecia areata, further expanding its therapeutic indications and enhancing its competitive position in the market.
See More
ImageneBio Reports $10.6M Q1 Net Loss Amid $30M Financing
- Financial Performance: ImageneBio reported a net loss of $10.6 million for Q1 2026, indicating ongoing pressure from operational and R&D expenditures, which may impact future liquidity.
- Cash Reserves: As of March 31, 2026, the company had cash, cash equivalents, and marketable securities totaling $117.2 million, providing sufficient liquidity to support short-term operations despite current losses.
- Financing Dynamics: ImageneBio's stock surged following a $30 million financing, reflecting market confidence in the company's future prospects and potentially providing funding for subsequent R&D and market expansion.
- Historical Performance Review: The disclosure of historical financial data offers investors a comprehensive background, aiding in the assessment of ImageneBio's long-term growth potential and risk management capabilities.
See More
ImageneBio Secures $30M Funding for Drug Development
- Funding Purpose Defined: ImageneBio plans to utilize the $30 million funding to support the development of IMG-007, focusing on alopecia areata and late-stage atopic dermatitis research, demonstrating the company's strong commitment to drug development.
- Clinical Trial Progress: IMG-007 is currently undergoing a Phase 2b ADAPTIVE trial, with topline results expected in 2027, and the trial continues to show a favorable safety and tolerability profile, enhancing investor confidence in its market potential.
- Stock Price Surge: ImageneBio's shares surged over 24% following the funding announcement, crossing its 50-day moving average for the first time since February 27, 2026, reflecting optimistic market sentiment towards the company's prospects.
- Investor Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish' amid extremely high message volumes, indicating strong market expectations for ImageneBio's future performance.
See More
ImageneBio Secures $30M in Private Placement Financing
- Financing Agreement: ImageneBio has entered into a definitive securities purchase agreement with certain institutional investors, expected to yield approximately $30 million in gross proceeds, reflecting market confidence in its future developments.
- Pre-Funded Warrant Issuance: The company is selling 5,770,335 pre-funded warrants at a price of $5.199 each, with an exercise price of $0.001 per share, a structure that helps reduce initial costs for investors and attract more capital.
- Diverse Investor Base: The financing is led by new investor Coastlands Capital, with participation from additional new investors like Trails Edge Capital Partners and existing investors such as Omega Funds and OrbiMed, showcasing a diversified investor base.
- Clear Use of Proceeds: ImageneBio plans to utilize the proceeds for further development of IMG-007 in alopecia areata and late-stage activities in atopic dermatitis, indicating the company's strategic focus and potential for future growth in therapeutic areas.
See More
ImageneBio Secures $30 Million in Private Placement Financing
- Funding Size: ImageneBio has entered into a definitive securities purchase agreement with institutional investors, expected to yield approximately $30 million, which will support further development of IMG-007 for alopecia areata and atopic dermatitis, thereby enhancing the company's R&D capabilities and market competitiveness.
- Investor Support: The financing is led by new investor Coastlands Capital and includes participation from new investors like Trails Edge Capital Partners and existing investors such as Omega Funds and OrbiMed, reflecting strong market confidence in ImageneBio and its products.
- Product Development Progress: ImageneBio's IMG-007, a non-depleting OX40 antagonist, is currently undergoing a Phase 2b ADAPTIVE clinical trial, with an amended protocol designed to showcase its unique therapeutic features, further advancing its market application.
- Market Demand: IMG-007 has already demonstrated promising clinical proof-of-concept in alopecia areata, addressing a significant unmet need for biologics with durable efficacy and a strong tolerability profile, which is expected to provide long-term growth potential for the company.
See More
Analysis of High Insider Ownership Growth Companies in Australia
- Market Optimism: Australian shares are nearing a 0.5% advance, driven by optimism surrounding geopolitical developments in the Middle East, as investors closely monitor the potential impacts on market stability and asset prices across various sectors, reflecting confidence in future growth.
- Attraction of High Insider Ownership: Growth companies with high insider ownership, such as Torque Metals (18.6%) and Magnetic Resources (33.6%), are particularly appealing in the current economic landscape due to their strong internal confidence and alignment with shareholder interests, making them noteworthy investment candidates.
- Meeka Metals' Performance Turnaround: Meeka Metals reported a significant turnaround with a net income of A$31.04 million for the half-year ending December 2025, forecasting robust annual earnings growth of over 54%, and despite past shareholder dilution, its stock trades at a substantial discount to estimated fair value, indicating strong growth potential.
- Southern Cross Electrical Engineering Outlook: Despite facing a net loss of A$12.78 million, Southern Cross Electrical Engineering is expected to achieve significant earnings growth of 75.2% annually over the next three years, driven by strong demand in electrical and communication services, with insider buying indicating confidence in future prospects.
See More
ImageneBio CEO to Present at Jefferies Global Healthcare Conference
- Conference Participation: ImageneBio CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026, and engage in one-on-one meetings, aiming to enhance the company's visibility and credibility among investors.
- Clinical Trial Progress: ImageneBio is conducting a Phase 2b clinical trial of IMG-007 for patients with moderate-to-severe atopic dermatitis, which is expected to yield significant clinical data that could advance the company's product development pipeline.
- Product Characteristics: IMG-007 is a receptor-targeting monoclonal antibody with an approximately 5-week half-life and non-T cell-depleting properties, showcasing potential advantages in immunotherapy that may attract increased investor interest.
- Future Plans: The company has completed a proof-of-concept trial for IMG-007 and plans to initiate a Phase 2 study in alopecia areata, further expanding its therapeutic indications and enhancing its competitive position in the market.
See More
ImageneBio Reports $10.6M Q1 Net Loss Amid $30M Financing
- Financial Performance: ImageneBio reported a net loss of $10.6 million for Q1 2026, indicating ongoing pressure from operational and R&D expenditures, which may impact future liquidity.
- Cash Reserves: As of March 31, 2026, the company had cash, cash equivalents, and marketable securities totaling $117.2 million, providing sufficient liquidity to support short-term operations despite current losses.
- Financing Dynamics: ImageneBio's stock surged following a $30 million financing, reflecting market confidence in the company's future prospects and potentially providing funding for subsequent R&D and market expansion.
- Historical Performance Review: The disclosure of historical financial data offers investors a comprehensive background, aiding in the assessment of ImageneBio's long-term growth potential and risk management capabilities.
See More
ImageneBio Secures $30M Funding for Drug Development
- Funding Purpose Defined: ImageneBio plans to utilize the $30 million funding to support the development of IMG-007, focusing on alopecia areata and late-stage atopic dermatitis research, demonstrating the company's strong commitment to drug development.
- Clinical Trial Progress: IMG-007 is currently undergoing a Phase 2b ADAPTIVE trial, with topline results expected in 2027, and the trial continues to show a favorable safety and tolerability profile, enhancing investor confidence in its market potential.
- Stock Price Surge: ImageneBio's shares surged over 24% following the funding announcement, crossing its 50-day moving average for the first time since February 27, 2026, reflecting optimistic market sentiment towards the company's prospects.
- Investor Sentiment Shift: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish' amid extremely high message volumes, indicating strong market expectations for ImageneBio's future performance.
See More
ImageneBio Secures $30M in Private Placement Financing
- Financing Agreement: ImageneBio has entered into a definitive securities purchase agreement with certain institutional investors, expected to yield approximately $30 million in gross proceeds, reflecting market confidence in its future developments.
- Pre-Funded Warrant Issuance: The company is selling 5,770,335 pre-funded warrants at a price of $5.199 each, with an exercise price of $0.001 per share, a structure that helps reduce initial costs for investors and attract more capital.
- Diverse Investor Base: The financing is led by new investor Coastlands Capital, with participation from additional new investors like Trails Edge Capital Partners and existing investors such as Omega Funds and OrbiMed, showcasing a diversified investor base.
- Clear Use of Proceeds: ImageneBio plans to utilize the proceeds for further development of IMG-007 in alopecia areata and late-stage activities in atopic dermatitis, indicating the company's strategic focus and potential for future growth in therapeutic areas.
See More
ImageneBio Secures $30 Million in Private Placement Financing
- Funding Size: ImageneBio has entered into a definitive securities purchase agreement with institutional investors, expected to yield approximately $30 million, which will support further development of IMG-007 for alopecia areata and atopic dermatitis, thereby enhancing the company's R&D capabilities and market competitiveness.
- Investor Support: The financing is led by new investor Coastlands Capital and includes participation from new investors like Trails Edge Capital Partners and existing investors such as Omega Funds and OrbiMed, reflecting strong market confidence in ImageneBio and its products.
- Product Development Progress: ImageneBio's IMG-007, a non-depleting OX40 antagonist, is currently undergoing a Phase 2b ADAPTIVE clinical trial, with an amended protocol designed to showcase its unique therapeutic features, further advancing its market application.
- Market Demand: IMG-007 has already demonstrated promising clinical proof-of-concept in alopecia areata, addressing a significant unmet need for biologics with durable efficacy and a strong tolerability profile, which is expected to provide long-term growth potential for the company.
See More
Analysis of High Insider Ownership Growth Companies in Australia
- Market Optimism: Australian shares are nearing a 0.5% advance, driven by optimism surrounding geopolitical developments in the Middle East, as investors closely monitor the potential impacts on market stability and asset prices across various sectors, reflecting confidence in future growth.
- Attraction of High Insider Ownership: Growth companies with high insider ownership, such as Torque Metals (18.6%) and Magnetic Resources (33.6%), are particularly appealing in the current economic landscape due to their strong internal confidence and alignment with shareholder interests, making them noteworthy investment candidates.
- Meeka Metals' Performance Turnaround: Meeka Metals reported a significant turnaround with a net income of A$31.04 million for the half-year ending December 2025, forecasting robust annual earnings growth of over 54%, and despite past shareholder dilution, its stock trades at a substantial discount to estimated fair value, indicating strong growth potential.
- Southern Cross Electrical Engineering Outlook: Despite facing a net loss of A$12.78 million, Southern Cross Electrical Engineering is expected to achieve significant earnings growth of 75.2% annually over the next three years, driven by strong demand in electrical and communication services, with insider buying indicating confidence in future prospects.
See More
